Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Cencora, Inc. (COR) — XLV Health Care · S&P 500 Profile |Cencora 介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Cencora, Inc. (COR) — Business, History & S&P 500 Profile |Cencora 介紹

Cencora company profile · pharmaceutical distribution, specialty & services · history · financial snapshot · S&P 500 rank #197 · Cencora 業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 31, 2026
Financials: FY2025 (ended Sep 30, 2025)
MARKET CAP
$63.13B
Oct 31, 2026 · StockAnalysis
S&P 500 WEIGHT
0.09%
Rank #197 · Oct 31, 2026 (Slickcharts)
FY2025 REVENUE
$321.33B
+9.3% YoY · operating income $2.63B
FY2025 NET INCOME
$1.55B
Attributable to Cencora · diluted EPS $7.96

SNAPSHOT

TickerCOR (NYSE)
CompanyCencora, Inc.
GICS sector / industryHealth Care (XLV) / Health Care Distributors
S&P 500 rank (by weight)#197 · 0.09% (Oct 31, 2026)
Sector rank (by index weight)#24 in Health Care (Oct 31, 2026)
HeadquartersConshohocken, Pennsylvania
FoundedAugust 28, 2001, by the merger of AmeriSource Health and Bergen Brunswig (renamed Cencora in 2023)
CEORobert P. Mauch (President & CEO)
EmployeesMore than 51,000 globally, ≈47,000 full-time (Sep 30, 2025, FY2025 10-K)
Market cap$63.13B (Oct 31, 2026)
SEC filingsEDGAR — CIK 0001140859

WHAT IT DOES

Cencora, formerly AmerisourceBergen, is a pharmaceutical solutions organization that sources and distributes branded, generic and specialty pharmaceuticals and provides services to healthcare providers, pharmacies and pharmaceutical and biotech manufacturers. It serves customers through a geographically diverse network of distribution service centers and other operations in the United States and select global markets.

FY2025 revenue was $321,332.8 million, up 9.3% from $293,958.6 million in FY2024. U.S. Healthcare Solutions supplied $290,982.0 million of that revenue, including human health distribution of $285,287.5 million and animal health of $5,694.5 million; International Healthcare Solutions supplied $30,366.3 million. Total segment operating income rose 15.8% to $4,223.0 million, while consolidated operating income was $2,628.6 million after goodwill impairment, acquisition-related and litigation items.

Growth in FY2025 was led by U.S. human health distribution (+9.7%), helped by specialty pharmaceuticals and by the January 2025 acquisition of Retina Consultants of America (RCA), and by drug utilization trends including GLP-1 products for diabetes and weight loss, as described in the 10-K. The business model is high-volume and thin-margin: consolidated operating income was 0.8% of revenue in FY2025.

BUSINESS SEGMENTS — FY2025 REVENUE

SegmentRevenueShareYoY
U.S. Healthcare Solutions$290.98B90.6%+9.7%
International Healthcare Solutions$30.37B9.4%+6.1%
Total revenue$321.33B100%+9.3%
Source: Cencora FY2025 Form 10-K MD&A (fiscal year ended Sep 30, 2025). Intersegment eliminations of $15.5 million are excluded from the two segment lines; consolidated revenue was $321,332.8 million. Shares computed from the 10-K segment table.

HISTORY

YearMilestone
2001Formed on August 28, 2001, by the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, as AmerisourceBergen Corporation
2023Expands contract research and consulting with the PharmaLex acquisition
2023Changes its name to Cencora, Inc. on August 30, 2023, and begins trading under the new name
2025Acquires an 85% interest in Retina Consultants of America (RCA) on January 2, 2025, for $4,042.0 million in cash plus contingent consideration

COMPETITIVE POSITION

  • Scale in distribution — one of three leading U.S. pharmaceutical wholesalers, alongside McKesson and Cardinal Health; scale in purchasing, warehousing automation and delivery frequency is the core advantage.
  • Specialty leadership — leading positions in distribution and services to health systems, community oncologists and retina specialists, where handling, cold chain and patient services matter more than price alone.
  • Services extension — contract research (PharmaLex), manufacturer services and patient-access programs extend revenue beyond the thin distribution margin.
  • Competition — McKesson and Cardinal Health contest the same pharmacy, hospital and manufacturer accounts; fee and service terms, not headline price, decide most renewals.

FINANCIAL SNAPSHOT — FY2025

Revenue$321.33B (+9.3% YoY, vs $293.96B in FY2024)
Operating income$2.63B (+20.8% YoY, vs $2.18B in FY2024)
Total segment operating income$4.22B (+15.8% YoY)
Net income attributable to Cencora$1.55B (vs $1.51B in FY2024)
Diluted EPS$7.96 (vs $7.53 in FY2024)
Goodwill impairment (FY2025)$723.9M, including PharmaLex goodwill
EmployeesMore than 51,000 globally (Sep 30, 2025)
Source: Cencora FY2025 Form 10-K (filed Nov 25, 2025; fiscal year ended Sep 30, 2025), consolidated statements and MD&A. Operating income is after goodwill impairment, acquisition-related intangibles amortization, and litigation and opioid-related items detailed in the 10-K.

KEY RISKS

  • Thin margins — at 0.8% of revenue, consolidated operating income leaves little room for a pricing, fee or working-capital miss.
  • Drug-pricing policy — the May 12, 2025 Executive Order on most-favored-nation prescription drug pricing and direct-to-consumer programs that may bypass traditional intermediaries is flagged in the 10-K as a risk to the distribution model.
  • Litigation and opioid exposure — litigation and opioid-related items remain a recurring charge in the operating-income reconciliation.
  • Customer and manufacturer concentration — large pharmacy chains, health systems and manufacturers can move volume at contract renewal, and manufacturer distribution policies can change fees.

WHY IT MATTERS FOR THE S&P 500

Cencora is the S&P 500’s pharmaceutical-distribution lever: at a 0.09% index weight and #24 in Health Care by index weight, its revenue tracks U.S. drug utilization — specialty launches, GLP-1 volumes and generic conversion — more directly than any drug manufacturer in the index.

Because it touches nearly every prescription channel, its results also read as a gauge of healthcare spending itself: when utilization rises, Cencora’s volumes rise first, even though its margin per dollar stays thin.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl)
FinancialsCencora FY2025 Form 10-K (SEC EDGAR, filed Nov 25, 2025; fiscal year ended Sep 30, 2025)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Cencora

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼COR(NYSE)
公司Cencora, Inc.
GICS 板塊/行業醫療保健(XLV)/醫療保健分銷商
標普500排名(按權重)#197 · 0.09%(2026 年 10 月 31 日)
板塊內排名(按指數權重)醫療保健第 #24(2026 年 10 月 31 日)
總部美國賓夕法尼亞州康舍霍肯
成立2001 年 8 月 28 日,由 AmeriSource Health 與 Bergen Brunswig 合併成立(2023 年更名為 Cencora)
行政總裁Robert P. Mauch(總裁兼行政總裁)
員工全球逾 51,000,約 47,000 全職(2025 年 9 月 30 日,FY2025 10-K)
市值$63.13B(2026 年 10 月 31 日)
SEC 申報EDGAR — CIK 0001140859

業務概覽

Cencora(前稱 AmerisourceBergen)是一家醫藥解決方案機構,採購並分銷品牌藥、仿製藥與專科藥,並為醫療服務提供者、藥房及製藥與生物科技製造商提供服務。公司透過遍佈美國與部分全球市場的分銷服務中心網絡服務客戶。

FY2025 收入為 $3,213.328 億,同比增長 9.3%(FY2024 為 $2,939.586 億)。美國醫療保健解決方案貢獻 $2,909.820 億,包括人體健康分銷 $2,852.875 億與動物健康 $56.945 億;國際醫療保健解決方案貢獻 $303.663 億。板塊營業利潤合計增長 15.8% 至 $42.230 億;合併營業利潤在商譽減值、收購相關與訴訟項目後為 $26.286 億。

FY2025 增長由美國人體健康分銷帶動(+9.7%),受惠於專科藥與 2025 年 1 月收購的 Retina Consultants of America(RCA),以及 10-K 所述藥物使用趨勢(包括糖尿病與減重用 GLP-1 產品)。業務模式是高週轉、薄利潤:FY2025 合併營業利潤僅佔收入 0.8%。

業務板塊 — FY2025 收入

板塊收入佔比同比
美國醫療保健解決方案$290.98B90.6%+9.7%
國際醫療保健解決方案$30.37B9.4%+6.1%
總收入$321.33B100%+9.3%
來源:Cencora FY2025 Form 10-K 管理層討論(財政年度截至 2025 年 9 月 30 日)。兩板塊線不含板塊間抵銷 $1,550 萬;合併收入為 $3,213.328 億。佔比按 10-K 板塊表計算。

歷史沿革

年份里程碑
2001於 2001 年 8 月 28 日由 AmeriSource Health Corporation 與 Bergen Brunswig Corporation 合併成立,名為 AmerisourceBergen Corporation
2023透過收購 PharmaLex 擴展合約研究與顧問業務
2023於 2023 年 8 月 30 日更名為 Cencora, Inc.,並以新名稱交易
2025於 2025 年 1 月 2 日以 $40.420 億現金加或有對價收購 Retina Consultants of America(RCA)85% 權益

競爭地位

  • 分銷規模——美國三大醫藥批發商之一(另兩家為 McKesson 與 Cardinal Health);採購、倉儲自動化與配送頻次的規模是核心優勢。
  • 專科領導地位——在醫療系統、社區腫瘤科與視網膜專科的分銷與服務上居領先地位,該等領域的處理、冷鏈與患者服務比單純價格更重要。
  • 服務延伸——合約研究(PharmaLex)、製造商服務與患者用藥計劃,把收入延伸至薄分銷毛利之外。
  • 競爭——McKesson 與 Cardinal Health 爭奪同一批藥房、醫院與製造商客戶;費用與服務條款而非名目價格決定大多數續約。

財務快照 — FY2025

收入$321.33B(同比 +9.3%,FY2024 為 $293.96B)
營業利潤$2.63B(同比 +20.8%,FY2024 為 $2.18B)
板塊營業利潤合計$4.22B(同比 +15.8%)
歸屬 Cencora 淨利潤$1.55B(FY2024 為 $1.51B)
攤薄每股盈利$7.96(FY2024 為 $7.53)
商譽減值(FY2025)$723.9M,包括 PharmaLex 商譽
員工全球逾 51,000(2025 年 9 月 30 日)
來源:Cencora FY2025 Form 10-K(2025 年 11 月 25 日申報;財政年度截至 2025 年 9 月 30 日)合併報表與管理層討論。營業利潤已扣除商譽減值、收購相關無形資產攤銷及訴訟與阿片類相關項目(10-K 詳述)。

主要風險

  • 薄利潤——合併營業利潤僅佔收入 0.8%,定價、費用或營運資金稍有差池即影響重大。
  • 藥價政策——2025 年 5 月 12 日最惠國處方藥定價行政命令及可能繞過傳統中介的直銷計劃,在 10-K 中被列為分銷模式的風險。
  • 訴訟與阿片類風險——訴訟與阿片類相關項目仍是營業利潤調節表中的經常性項目。
  • 客戶與製造商集中度——大型連鎖藥房、醫療系統與製造商可在合約續約時轉移銷量,製造商分銷政策亦可改變費用。

對標普500的重要性

Cencora 是標普500中醫藥分銷的槓桿:指數權重 0.09%、醫療保健板塊指數權重第 #24,其收入比指數中任何製藥商都更直接地追蹤美國藥物使用量——專科新藥上市、GLP-1 銷量與仿製藥轉換。

由於它觸及幾乎所有處方渠道,其業績亦是醫療開支本身的讀數:使用量上升時,Cencora 的銷量最先上升,即使每美元毛利維持微薄。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取)
財務Cencora FY2025 Form 10-K(SEC EDGAR,2025 年 11 月 25 日申報;財政年度截至 2025 年 9 月 30 日)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Cencora

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · COR
Data as of Oct 31, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · NIKE, Inc. (NKE) — XLY Consumer Discretionary · S&P 500 Profile |耐克介紹Next · Cardinal Health, Inc. (CAH) — XLV Health Care · S&P 500 Profile |康德樂介紹

Entered 2026-10-31 11:33 · updated 2026-11-14 23:12 · rev 6